The Magazine of Corporate Responsibility

Tag Archive for ‘Xyrem’

First Amendment Claims Seen as Rx for Drug Makers, Headache for Consumers

Decisions in recent legal cases are fueling debate about whether the First Amendment’s protection of commercial speech could undermine the FDA’s ability to prevent drug marketing abuses. Some worry that changing political dynamics – especially the anti-regulatory aims of the Trump administration and Republican-dominated Congress – could free drug makers to push the boundaries of the law.

Doctors Avoid Penalties in Suits Against Medical Firms

At least 15 drug and medical-device companies have paid $6.5 billion since 2008 to settle accusations of marketing fraud or kickbacks. However, none of the more than 75 doctors named as participants were sanctioned, despite allegations of fraud or of conduct that put patients at risk, a review by ProPublica found.